Phaeochromocytomas and sympathetic paragangliomas

Research output: Contribution to journalArticleAcademicpeer-review

51 Citations (Scopus)

Abstract

Background: About 24 per cent of phaeochromocytomas (PCCs) and sympathetic paragangliomas (sPGLs) appear in familial cancer syndromes, including multiple endocrine neoplasia type 2, von Hippel-Lindau disease, neurofibromatosis type 1 and PCC-paraganglioma syndrome. Identification of these syndromes is of prime importance for patients and their relatives. Surgical resection is the treatment of choice for both PCC and sPGL, but controversy exists about the management of patients with bilateral or multiple tumours. Methods: Relevant medical literature from PubMed, Ovid and Embase websites until 2009 was reviewed for articles on PCC, sPGL, hereditary syndromes and their treatment. Discussion: Genetic testing for these syndromes should become routine clinical practice for those with PCC or sPGL. Patients should be referred to a clinical geneticist. Patients and family members with proven mutations should be entered into a standardized screening protocol. The preferred treatment of PCC and PGL is surgical resection; to avoid the lifelong consequences of bilateral adrenalectomy, cortex-sparing adrenalectomy is the treatment of choice.
Original languageUndefined/Unknown
Pages (from-to)1381-1392
Number of pages12
JournalBritish Journal of Surgery
Volume96
Issue number12
DOIs
Publication statusPublished - 2009

Research programs

  • EMC MGC-02-96-01
  • EMC MM-01-39-01
  • EMC MM-03-24-01
  • EMC MM-03-47-11

Cite this